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Abstract
Background: Although metastatic colon cancer is a leading cause of cancer death worldwide, the molecular mechanisms
that enable colon cancer cells to metastasize remain unclear. Emerging evidence suggests that metastatic cells develop by
usurping transcriptional networks from embryonic stem (ES) cells to facilitate an epithelial-mesenchymal transition (EMT),
invasion, and metastatic progression. Previous studies identified HMGA1 as a key transcription factor enriched in ES cells,
colon cancer, and other aggressive tumors, although its role in these settings is poorly understood.
Methods/Principal Findings: To determine how HMGA1 functions in metastatic colon cancer, we manipulated HMGA1
expression in transgenic mice and colon cancer cells. We discovered that HMGA1 drives proliferative changes, aberrant crypt
formation, and intestinal polyposis in transgenic mice. In colon cancer cell lines from poorly differentiated, metastatic tumors,
knock-down of HMGA1 blocks anchorage-independent cell growth, migration, invasion, xenograft tumorigenesis and three-
dimensional colonosphere formation. Inhibiting HMGA1 expression blocks tumorigenesis at limiting dilutions, consistent with
depletion of tumor-initiator cells in the knock-down cells. Knock-down of HMGA1 also inhibits metastatic progression to the
liver invivo. In metastatic coloncancer cells,HMGA1 induces expression of Twist1, a geneinvolved inembryogenesis, EMT, and
tumor progression, while HMGA1 represses E-cadherin, a gene that is down-regulated during EMT and metastatic progression.
In addition, HMGA1 is among the most enriched genes in colon cancer compared to normal mucosa.
Conclusions: Our findings demonstrate for the first time that HMGA1 drives proliferative changes and polyp formation in
the intestines of transgenic mice and induces metastatic progression and stem-like properties in colon cancer cells. These
findings indicate that HMGA1 is a key regulator, both in metastatic progression and in the maintenance of a stem-like state.
Our results also suggest that HMGA1 or downstream pathways could be rational therapeutic targets in metastatic, poorly
differentiated colon cancer.
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Introduction
Despite recent progress in colorectal cancer screening and
treatment, metastatic colorectal cancer remains a leading cause of
cancer death worldwide [1–2]. The molecular mechanisms that
enable cancer cells to metastasize are poorly understood, although
emerging evidence indicates that transcriptional networks required
for stem cell properties during embryogenesis are co-opted during
metastatic progression [3–4]. Recent studies identified HMGA1 as
a key transcription factor enriched in human embryonic stem (ES)
cells [3], hematopoietic stem cells [5–8], refractory leukemia [6–
7,9] and high-grade/poorly differentiated cancers from the breast,
brain, and bladder [3]. Moreover, tumors overexpressing HMGA1
and eight other ES transcription factor genes had decreased
survival, underscoring the importance of these genes in tumor
progression [3]. More recently, we found that HMGA1 protein
levels correlate with poor differentiation status and decreased
survival in pancreatic cancer, further implicating HMGA1 in an
undifferentiated, stem-like state and tumor progression [10]. The
HMGA1 gene encodes the HMGA1a and HMGA1b chromatin
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by altering chromatin structure and assembling transcription
factor complexes at specific promoters [11–18]. Previous studies
demonstrate that HMGA1 induces oncogenic properties in
cultured cells [19–27] and causes aggressive tumors in transgenic
mice [9,28–32]. The precise molecular pathways regulated by
HMGA1 in transformation, however, are only beginning to
emerge and studies to elucidate HMGA1 transcriptional networks
are likely to uncover fundamental pathways involved in tumor
progression and development.
Here, we report for the first time that the HMGA1 drives
proliferative changes and polyp formation in the intestines of
transgenic mice and directs molecular pathways important in
tumor progression and stem cell properties in human colon cancer
cells. Taken together, these findings suggest that HMGA1 promotes
tumor progression in colon cancer by reprogramming colonic
epithelium to a stem-like state.
Materials and Methods
Ethics Statement
All animal experiments were conducted in accordance with a
protocol approved by the Johns Hopkins University Animal Care
and Use Committee (protocol# MO08M263). All mice were
housed in a sterile environment where they had free access to food
and water as outlined in our institutional guidelines.
Quantitative reverse transcription-PCR (qRT-PCR)
analysis. RNA was prepared as we described [9,27]. The
primers for HMGA1 [28], Twist, Vimentin, E-cadherin, FOXC2,
Snail1, Slug, TCF-3, Twist1, Twist2, SFH1B) were previously
reported [4]. GAPDH primers are commercially available (Applied
Biosystems). qRT-PCR reactions were done in triplicate and
repeated at least once.
Western analysis. Western analyses were performed as we
described [9,19–20,33] using a commercial HMGA1 antibody
(Abcam, catalogue #AB4078) diluted 1:1000 and b-actin (Cell
Signaling, catalogue #4967) diluted 1:1000 as an endogenous
control.
Cell lines. HCT116 (CCL-247; American Type Culture
Collection) and SW480 (CCL-228; American Type Culture
Collection) were cultured as recommended. Transfected cells
were selected in puromycin (3 ug/ml).
Growth Curves. Cellular growth rates were determined as
we previously described [19–20,26–29,33].
Anchorage-independentcellgrowthinsoftagar,migration,
and invasion assays. These assays were performed as we
Figure 1. HMGA1 causes proliferative changes, ectopic crypt formation, and polyps in transgenic mice. (A) The HMGA1 transgenic
intestines are hyperemic with increased weight compared to controls (n=7 in each group; p=0.000000138 by student’s t-test.) (B) Polyp number in
the transgenics and controls (n=7 in each group; p=0.000426 by student’s t-test). The intestinal spreads (right panels) are stained with 1.5%
methylene blue to accentuate polyps for counting. (C) Hematoxylin and eosin staining of the small and large intestine shows marked proliferative
changes in the transgenics (bar=50 mm). (D) Expansion of the proliferative zone resulting in a diffusely hyperplastic appearance of the mucosa and
cystically dilated crypts in the transgenics. The higher power view of the small intestinal mucosa shows formation of ectopic crypt foci (arrows).
doi:10.1371/journal.pone.0030034.g001
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with 60,000 cells/well and invasion assays were done with 20 ul of
growth factor reduced matrigel.
Colonosphere assay. Colonosphere assays were performed
as previously described [34].
In vivo metastasis assay. This assay was performed as
previously described [35] with cells (10
5) injected per mouse
(NOD/Shi-scid/IL-2Rc
null; Jackson Laboratory).
Xenograft tumorigenicity. These studies were done in nude
(nu2/2) mice as we described [19–20].
Vectors. The short hairpin RNA (shRNA) interference
plasmid for HMGA1 has been described [36]. The empty
shRNA vector was used as a control.
Immunohistochemical analysis. Tissue sections (4 mm
thick) from small and large intestines of transgenic and control
mice were generated and deparaffinized in xylene and then
hydrated in a graded alcohol series. Heat-induced epitope retrieval
was performed in an autoclave for 10 minute in sodium citrate
buffer (pH 6.0). Endogenous peroxidase activity was inactivated
by incubation of the sections in 4% H2O2 for 5 minutes. After
rinsing in phosphate-buffered saline, the sections were incubated
with rabbit monoclonal anti-Ki-67 antibody (clone 30-9, Ventana,
Tucson, AZ, catalogue #790-4286) for 1 hour at room
temperature. Positive staining was visualized with the DAKO
EnVision Plus-HRP detection kit (DAKO, Carpinteria, CA)
according to the manufacturer’s instructions. Ki-67 positive cells
were counted in 5 randomly selected fields from comparable areas
in the small and large intestine from transgenic and control mice at
206 magnification. A total of 100 crypts for each mouse were
counted from stained sections from transgenic and control mice (2
mice/group).
Cell morphology and size determinations. Cells were
plated and allowed to grow to 80% confluency. Photographs for
morphologic assessment and diameter measurements were
obtained using the Zeiss Inverted M-scope with the Olympus
DP72 Camera and Software (JHMI Confocal Facility). At least
Figure 2. HMGA1 drives proliferation in intestinal mucosa and is overexpressed in colon cancer. (A) Ki-67 staining of small and large
intestines from HMGA1 transgenics (bottom panels) and control mice (top panels) show a significant increase in Ki-67 immunoreactivity in the HMGA1
transgenics (206magnification). (B) Ki-67 positive cells in HMGA1 transgenic and control mice were enumerated in crypts of the small and large
intestine at 206magnification. The mean 6 the standard deviations of Ki-67 positive cells per crypt for 100 crypts for each pair of mice at each
location are shown. Highly significant differences were demonstrated between transgenics and controls in both the small and large intestines
(p,0.00001, student’s t-test) (C) HMGA1 expression was assessed by qRT-PCR and increased in the primary, high grade (grade 3–4) colon
adenocarcinomas compared to adjacent, normal colonic tissue. b-actin was used to control for loading and the normal tissue was arbritrarily assigned
a value of 1.0. (D) Western blot analysis for HMGA1 and control protein (GAPDH) was performed on 3 tumors with sufficient sample and showed
increasing HMGA1 protein with decreasing differentiation and increasing invasiveness or frank metastasis. The grade, differentiation status,
invasiveness, and presence of metastatic disease are indicated.
doi:10.1371/journal.pone.0030034.g002
HMGA1 in Colon Cancer and Stem Cell Properties
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30034five random fields were photographed for each cell line with or
without HMGA1 knock-down. The greatest diameter (mm) was
measured for 700–1000 cells from each group. The greatest
diameters were represented as the mean 6 the standard deviation;
significance was determined using the student’s t-test.
Results
HMGA1a transgenics develop polyps and expansion in
the stem cell compartment
To define the role of HMGA1 in tumorigenesis, we engineered
transgenic mice with the murine hmga1a transgene driven by the
H2K promoter and immunoglobulin mu enhancer [9,27–29]. As
previously reported, all mice succumb to aggressive lymphoid
malignancy [9] and the females develop uterine sarcomas [28–29].
To determine if HMGA1 promotes neoplastic transformation in
intestinal epithelium, we investigated the intestines of these mice.
The transgene is expressed in the small and large intestines by 4 to
7-fold above that found in controls (Fig. S1). At necropsy, the
intestines are hyperemic with a thickened mucosa and increased
weight compared to controls (Fig. 1A–D). Histologically, both
large and small intestines exhibit marked proliferative changes,
ectopic crypt formation, and polyp formation (Fig. 1C–D). There
was a significant increase in Ki-67 in both the small and large
intestine, a marker of proliferation (Fig. 2A–B). The increase in
crypt number suggests that these mice could have expansion of the
intestinal stem cell compartment [37].
HMGA1 is enriched in human colon carcinomas
High levels of HMGA1 protein or mRNA were reported in
colon cancer cell lines or primary tumors in a small pilot study
[38]. To determine if HMGA1 is overexpressed in larger studies of
primary colon cancers, we queried gene expression profile analysis
of primary colon cancers from six independent studies through the
Figure 3. HMGA1 is required for migration, invasion, anchorage-independent cell growth, and limiting dilution tumorigenicity. (A)
Transfection with an shRNA knockdown vector for HMGA1 in highly aggressive, poorly differentiated human colon cancer cells (HCT116 and SW480)
results in a significant decrease in HMGA1 protein. (B) Migration and invasion were assessed in control (dark bars) and HMGA1 knock-down (open
bars) colon cancer cells (HCT116 and SW480). The graph shows the mean 6 the standard deviation from 2 experiments done in triplicate. (p-values
determined by student’s t-tests are shown). (C) Anchorage-independent cell growth in soft agar in control (dark bars) and HMGA1 knock-down (open
bars) colon cancer cells (HCT116 and SW480). All foci .50 mm were counted. The bar graph shows the mean 6 the standard deviation from two
experiments done in triplicate. (p-values determined by student’s t-tests are shown). (D) The table shows that knock-down of HMGA1 blocks tumor
formation at limiting dilutions. The photograph shows representative nude mice 4 weeks following injection with control or HMGA1 knock-down in
HCT116 cells (10
5/injection). No tumors formed in the HMGA1 knock-down cells.
doi:10.1371/journal.pone.0030034.g003
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TM public database (Compendia Bioscience, Ann
Arbor, MI). We found that HMGA1 is highly enriched in colon
adenocarcinoma compared to normal tissue in 5/5 prior studies.
In all of these studies, HMGA1 was among the top 10% of
enriched genes, and in 4 studies, it was among the top 1–3% of
enriched genes. In a pilot of 10 primary, high-grade (grade III–IV)
colon cancers (a generous gift from Bert Vogelstein), we found that
HMGA1 expression was increased in most colon cancer samples
(8/11) compared to adjacent normal tissue from the same patient.
Moreover, the mean HMGA1 expression from all tumors was
increased by 3-fold compared to the adjacent control tissue
(Fig. 2C). We also assessed protein expression in a subset of
primary colon tumors with sufficient material and found the
highest levels of HMGA1 protein in the high grade, metastatic
tumors with undetectable levels in the adjacent normal tissue
(Fig. 2D).
HMGA1 is required for anchorage-independent cell
growth, migration, invasion, and tumorigenesis in colon
cancer cells
To investigate the functional role of HMGA1 in colon cancer,
we inhibited HMGA1 expression in two colon cancer cell lines
derived from poorly differentiated (grade 4), metastatic colon
cancers (HCT116 and SW480) using an shRNA approach.
Transfection of cells with an HMGA1 shRNA vector resulted in
a significant, stable decrease in HMGA1 protein (Fig. 3A) in the
shRNA cells compared to cells transfected with the control vector.
We found that knock-down of HMGA1 blocked anchorage-
independent cell growth or foci formation in soft agar, migration,
and invasion in both HCT116 and SW480 cells (Fig. 3B–C).
Moreover, no tumors formed in nude mice after injection of
HCT116 cells with HMGA1 knock-down (10
5 or 10
4 cells), while
Figure 4. HMGA1 is required for colonsphere formation and metastatic progression in vivo. (A) Three-dimensional colonosphere
formation in control (dark bars) and HMGA1 knock-down (open bars) colon cancer cells (HCT116 and SW480). Spheres were counted after 10 days.
The graph shows the mean 6 the standard deviation from 3 experiments done in triplicate. (p-values determined by student’s t-tests are shown). (B)
Metastatic foci in the liver were counted 5 weeks after injection of control (dark bars) or HMGA1 knock-down (open bars) HCT116 cells (1610
5) into
the spleens of nude mice. The bar graph shows the mean 6 the standard deviation of metastatic foci from two experiments done in triplicate. The
mice injected with control cells (black bar) were compared to mice injected with HMGA1 knock-down cells (open bars; p-values determined by
student’s t-tests are shown). (C) Gross photographs of metastatic foci to the liver following injection of HCT116 cells into the spleens of jude mice.
The left liver is taken from a representative mouse injected with control cells; the right liver is taken from a representative mouse injected with
HMGA1 knock-down cells. Photographs depict representative livers from mice receiving control or HMGA1 knock-down cells. (D) Histologic
examination of the livers confirmed that the metastatic foci are significantly increased from the spleens injected with control cells compared to
HMGA1 knock-down cells (Bar=100 mm).
doi:10.1371/journal.pone.0030034.g004
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(Fig. 3D). There was no significant difference in growth rates in the
cell lines with or without HMGA1 knock-down in vitro (Fig. S2),
indicating that the HMGA1 shRNA was not toxic to the colon
cancer cells. These results demonstrate that HMGA1 drives
cellular properties required for both tumor initiation (anchorage-
independent cell growth, tumorigenesis) and tumor progression
(migration, invasion).
HMGA1-dependent stem cell properties in colon cancer
cells
Because HMGA1 is enriched in stem cells [5–8] and causes
changes in the mouse intestine that could be consistent with
expansion in the intestinal stem cell compartment, we sought to
determine if HMGA1 is involved in stem cell properties in colon
cancer cells. To this end, we assessed three-dimensional colono-
sphere formation in the colon cancer cell lines with or without
knock-down of HMGA1. We discovered a significant decrease in
the number of colonospheres in both the HCT116 and SW460
cells with HMGA1 knock-down compared to controls (Fig. 4A).
These findings indicate that HMGA1 is necessary for this stem cell
phenotype (three-dimensional growth) in colon cancer cells. In
limiting dilution tumorigenicity experiments, knock-down of
HMGA1 blocked tumor formation when 104 or 105 cells were
injected, whereas tumors formed in the control cells. Tumors
formed in both control and knock-down groups if 106 cells were
injected (Fig. 3D). These results indicate that knock-down of
HMGA1 depletes the tumor-initiator cells.
HMGA1 is required for metastatic progression in colon
cancer
To determine if HMGA1 is required for tumor progression, we
used a preclinical model for metastatic progression in colon
cancer [35]. HCT116 colon cancer cells were injected directly
into the spleens of immunodeficient mice and liver metastases
were assessed after 5 weeks. Strikingly, we found a marked
decrease in metastatic foci in the livers from mice injected with
HMGA1 knock-down cells (Fig. 4B–C). These results underscore
the critical role of HMGA1 in metastatic progression in this
model.
Figure 5. HMGA1 dysregulates genes involved in EMT in metastatic colon cancer cells. (A) In HCT116 cells, Twist1, and Vimentin mRNA
expression were repressed by qRT-PCR in the HMGA1 knock-down cells compared to control cells. E-cadherin and other EMT genes were not affected
in these cells. (p-values determined by the student’s t-tests are shown). (B) In SW480 cells, Vimentin is repressed and E-cadherin is induced in the cells
with HMGA1 knock-down. (p-values determined by the student’s t-tests are shown).
doi:10.1371/journal.pone.0030034.g005
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Vimentin
Because recent studies link EMT to epithelial stem cell
properties [3–4], we sought to determine if HMGA1 regulates
EMT genes in colon cancer. To this end, we assessed expression
levels of 11 genes previously shown to play an important role in
EMT and cancer initiator cells [4]. In the HCT116 cells, we found
that both Twist1 and Vimentin were significantly repressed in cells
with HMGA1 knock-down (Fig. 5A), indicating that HMGA1
induces their expression. In SW480 cells, E-cadherin is up-regulated
in the knock-down cells, suggesting that HMGA1 normally
represses its expression (Fig. 5B). Twist1 was also significantly
repressed in the SW480 knock-down cells, although less than what
we observed in the HCT116 cells. Taken together, our studies
suggest that HMGA1 promotes tumor progression through
transcriptional networks that facilitate metastatic progression and
a stem-like state, at least in part, by inducing the Twist1 and
Vimentin, while repressing E-cadherin. Of note, there were no
changes in cell morphology or size in the knock-down cells (Fig.
S3), suggesting that down-regulation of HMGA1 in these cells is
not sufficient to induce morphologic changes consistent with a
reversion to a more epithelial state when grown as a monolayer. As
noted previously, there were significant alterations in growth
characteristics when grown in an anchorage-independent fashion
or after implantation into mice. The variation in EMT genes
modulated by HMGA1 in these two different cell lines likely
reflects the differing milieu and reprogramming potential in the
cancer cells based on underlying genetic and epigenetic changes.
Discussion
Metastatic colon cancer is highly lethal and the incidence is rising,
particularly in younger individuals [1–2]. Current therapies are
limited by the emergence of metastatic cancer cells that are resistant to
treatment. Recent evidence suggests that these refractory cells develop
because they co-opt the cellular networks involved in embryonic
development and become capable of metastasizing and evading
therapy [3–4]. The HMGA1 oncogene was recently identified as a key
transcription factor enriched in ES cells and high grade tumors with
poor outcomes [3], although its function in these settings has
remained elusive. This gene is a member of the HMGA gene family,
that also includes HMGA1 [11–18] and HMGA2 [31,39–40]. All
HMGA proteins are small, low molecular weight (thus high mobility
group proteins) with an A T - h o o kD N Ab i n d i n gd o m a i nt h a tm e d i a t e s
binding to AT-rich regions in the minor groove of chromatin.
HMGA1 and other AT-hook proteins are thought to function by
modulating chromatin structure and gene expression [15–18,41–42].
Here, we show for the first time that HMGA1 induces proliferative
changes and polyp formation in the intestines of transgenic mice.
Moreover, HMGA1 is required for limiting dilution tumorigenesis in
vivo along with 3-dimensional colonosphere formation in vitro,b o t ho f
which are phenotypes characteristic of epithelial stem cells.
Furthermore, inhibiting HMGA1 expression blocks not only transfor-
mation properties involved in tumor initiation (anchorage-indepen-
dent cell growth, tumorigenicity), but also cellular characteristics that
promote metastatic progression (invasion and migration). We also
discovered that HMGA1 is required for metastatic progression to the
liver in vivo. Notably, several recent studies have also shown that
HMGA1 is enriched in normal stem cells, including embryonic and
hematopoietic stem cells [3–8], in addition to poorly differentiated, or
refractory stem-like cancers [8–32], suggesting that HMGA1 helps to
drive a stem-like state, both in normal development and cancer.
HMGA1 is also highly expressed during embryogenesis, with low or
undetectable expression in most differentiated, adult tissues [43].
To determine how HMGA1 orchestrates tumor progression
and stem cell phenotypes, we investigated expression of genes that
have been previously shown to be important in EMT, develop-
ment, and tumor initiator cells [4]. In HCT116 cells, we found
that HMGA1 up-regulates expression of both Twist1 and Vimentin.
In SW480 cells, HMGA1 also up-regulates Twist1, while it
represses E-cadherin. E-cadherin did not change in the HCT116
colon cancer cells with knock-down of HMGA1, which could
reflect stable silencing of E-cadherin in these mesenchymal, highly
metastatic colon cancer cell lines. The transcriptional networks
regulated by HMGA1 likely depends upon the cellular milieu and
underlying genetic and epigenetic characteristics.
In summary, our studies provide the first evidence linking
HMGA1 to cellular properties and transcriptional networks
important in stem cells, EMT, and metastatic progression in
colon cancer. Although further work is needed, these results
underscore the role of HMGA1 as a key regulator in tumor
progression and a stem-like state in colon cancer and suggest that
targeting HMGA1 pathways could be beneficial in therapy for
colon cancer. Because HMGA1 is enriched in embryonic stem
cells, tissue-specific stem cells, and virtually all aggressive tumors
studied to date, our findings are likely to relevant not only to
diverse human cancers, but also to normal development.
Supporting Information
Figure S1 HMGA1 transgene expression throughout the
small and large intestines in the transgenic (TG) mice
compared to wildtype (WT) controls. qRT-PCR for
HMGA1 and the control gene, GAPDH, was performed from
tissue obtained throughout the small intestine (duodenum,
jejunum, and ileum) and large intestine (ascending colon,
designated A colon, and descending colon, designated D colon)
from the TG and WT mice. HMGA1 expression in the TG
intestines is increased by 4 to 8-fold above that observed in the
WT mice, which was arbitrarily assigned a value of 1. All qRT-
PCR reactions were done in triplicate and repeated at least once.
(TIF)
Figure S2 Proliferation rates in HCT116 or SW480 colon
cancer cells with HMGA1 knock-down or control vector.
(A) Growth rates of the HCT116 cells transfected with the HMGA1
shRNA vector to knock-down HMGA1 (red squares) or control
vector (blue circles) show a similar proliferation rate. Standard
deviations are #10% and therefore not visible. (B) Growth rates of
the SW480 cells transfected with the control vector (blue circles) or
HMGA1 shRNA vector (red squares) show a similar proliferation
rate. Standard deviations are #10% and therefore not visible.
(TIF)
Figure S3 HMGA1 knock-down results in alterations in
EMT genes without changes in cell morphology. (A)
Knock-down of HMGA1 in HCT116 cells does not result in
changes in cell morphology or diameter compared to controls. (B)
Knock-down of HMGA1 in SW480 cells does not result in
changes in cell morphology or diameter compared to controls.
Photographs were taken of live cells using a 106objective; scale
bar, 100 mm.
(PPTX)
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